In The News

Califf’s Return as FDA Head Will Give Drug Competition a Boost

Stacy Cline Amin

12 Nov 2021

Stacy Cline Amin spoke to Bloomberg Law for an article looking at how Robert Califf, in his return as commissioner of the Food and Drug Administration (FDA), will likely prioritize improving drug competition and boosting patient access to innovative treatments.

According to Stacy, the increased attention to the FDA’s role in drug pricing marks a change from previous years.

“One of the things that has been interesting in this administration is seeing FDA wade into discussions that it has traditionally tried very hard to not be involved in, like patent law discussions,” Stacy said. She added that the FDA has typically avoided discussions on drugmaker patent practices, such as filing patents for the sole purpose of weeding out competitors.

Read the full article (subscription required).



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.